FRANK KOLB

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency (generally, no specific legislation). Issues related to 340B program nondiscrimination and contract pharmacy arrangements (generally, no specific legislation). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation).

Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain (generally, no specific legislation). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). Provisions related to site neutral payments (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation).

The Equitable Community Access to Pharmacist Services Act, including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation).

Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to pharmacy benefit manager (PBM) abuses and transparency, including support for the following bills: the Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), the PBM Accountability Act (H.R. 2679), the Modernizing and Ensuring PBM Accountability Act (S. 2973), and the Pharmacy Benefit Manager Reform Act (S. 1339). Issues related to 340B program nondiscrimination and contract pharmacy arrangements, including support for the following bills: The PROTECT 340B Act (H.R. 2534) and the 340B Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act of 2024 (H.R. 7635). Issues related to manufacturer attempts to undercut the 340B program (generally, no specific legislation). Issues related to pharmacy residency funding, including support for the Rebuild Americas Health Care Schools Act of 2024 (S. 5397/H.R. 10225). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). The Biosimilar Red Tape Elimination Act (S. 2305) and the Affordable Prescriptions for Patients Act of 2023 (S. 150), issues related to accelerating biosimilar adoption.

Issues related to intravenous (IV) fluid shortages following Hurricane Helene (generally, no specific legislation). Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain, including support for the Drug Shortage Prevention and Mitigation Act. Issues related to COVID-19 response and post-public health emergency recommendations, including telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided vaccinations for COVID/flu/pediatric illnesses, COVID-19 testing, emergency HIV prophylaxis, initiation of oral antivirals for flu/COVID, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Patient access to comprehensive reproductive healthcare (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). The Lower Costs, More Transparency Act (H.R. 5378) and the Site-based Invoicing and Transparency Enhancement (SITE) Act (S. 1869), provisions related to site neutral payments. The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 7153/S. 3679), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation).

The Equitable Community Access to Pharmacist Services Act (H.R. 1770/S. 2477) and the Pharmacy and Medically Underserved Areas Enhancement Act (S. 1491), provisions related to Medicare coverage for all PREP Act services and COVID-19 response recommendations, including reimbursement for pharmacist provision of testing and vaccination. Issues related to telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS (generally, no specific legislation). Issues related to continuation of Public Readiness and Emergency Preparedness Act (PREP Act) allowances (generally, no specific legislation). Issues related to National Coverage Determination for pre-exposure prophylaxis (PrEP) for HIV prevention that would shift coverage of these services from Medicare Part D to Part B (generally, no specific legislation).

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS